This is CuraTeQ’s third biosimilar to be approved by EMA after the approval of Dyrupeg in April 2025 and Zefylti in February ...

As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer ...

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for ...

Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogsJaguar is exploring the possib ...

Enrollment in company’s first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for ...

Partner Therapeutics, Inc. (PTx) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of PTx's Marketing ...

GSK said the European Medicines Agency's committee responsible for human medicines has recommended the approval for its Blenrep drug. The U.K. pharma company on Friday said an approval decision by ...

ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare ...

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial Provided by GlobeNewswire May 12, 2025, 5:40:00 AM ...

CAMBRIDGE, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today ...

Grenoble, France, April 2nd, 2025 - Averoa, a biopharmaceutical company bringing innovative therapeutic solutions to people with renal diseases, today announces a positive opinion from the European ...